Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 20/20 | 0.68 |
| ▸ | MC3R | P41968 | 6/20 | 0.64 |
| ▸ | MC1R | Q01726 | 6/20 | 0.64 |
| ▸ | MC5R | P33032 | 5/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3151590 | 0.85 | MC4R (0.80) | MC4RMC3RMC1RMC5R | |
| SCHEMBL5934929 | 0.85 | MC4R (0.80) | MC4RMC3RMC1RMC5R | |
| SCHEMBL3143486 | 0.84 | MC4R (0.78) | MC4RMC3RMC1RMC5R | |
| SCHEMBL5887867 | 0.83 | MC4R (0.64) | MC4RMC3RMC1R | |
| Bicarbonate SCHEMBL3149384 | 0.82 | MC4R (0.76) | MC4RMC3RMC1RMC5R | |
| SCHEMBL5934677 | 0.82 | MC4R (0.80) | MC4RMC3RMC1RMC5R | |
| SCHEMBL5934963 | 0.82 | MC4R (0.77) | MC4RMC3RMC1RMC5R | |
| SCHEMBL5934827 | 0.82 | MC4R (0.75) | MC4RMC3RMC1RMC5R | |
| SCHEMBL5934386 | 0.82 | MC4R (0.75) | MC4RMC3RMC1RMC5R | |
| SCHEMBL3151174 | 0.82 | MC4R (0.64) | MC4RMC3RMC1RMC5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1716135-B1 | PIPERIDINYLCARBONYL-PYRROLIDINES AND THEIR USE AS MELANOCORTIN AGONISTS | PFIZER LTD (GB) | 2011-06-01 | — | — | EP | disclosed |
| US-7649002-B2 | (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists | PFIZER INC (US) | 2010-01-19 | — | — | US | disclosed |
| US-20080269233-A1 | Piperidinoyl-Pyrrolidine and Piperidinoyl-Piperidine Compounds | ANDREWS MARK DAVID | 2008-10-30 | — | — | US | disclosed |
| EP-1581480-B1 | CYCLOPENTYL-SUBSTITUTED GLUTARAMIDE COMPOUNDS AS ENDOPEPTIDASE-V INHIBITORS | PFIZER LTD (GB) | 2006-08-23 | — | — | EP | disclosed |
| US-7045653-B2 | cyclopentyl substituted glutaramide derivatives; inhibitors of neutral endopeptidase which may be used to treat cardiovascular disorders, especially hypertension | PFIZER, INC. (US) | 2006-05-16 | — | — | US | disclosed |
| US-20050176772-A1 | Pharmaceutically active compounds | PFIZER INC | 2005-08-11 | — | — | US | disclosed |
| US-20050075392-A1 | Novel pharmaceuticals | DACK KEVIN NEIL (GB) | 2005-04-07 | — | — | US | disclosed |
| US-20040138274-A1 | Cardiovascular disorders; hypotensive agents; endopeptidase inhibitor; sexual disorders | DACK KEVIN NEIL (GB) | 2004-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075392-A1 | Novel pharmaceuticals | MME, ECE1, ECE2 | MC4R 1638/4885MC3R 1110/4885MC1R 2838/4885 |
| US-20080269233-A1 | Piperidinoyl-Pyrrolidine and Piperidinoyl-Piperidine Compounds | GPR4, GPR119, PRLHR | MC4R 4/4885MC3R 86/4885MC1R 185/4885 |
| US-20050176772-A1 | Pharmaceutically active compounds | MC4R, MC3R, MC5R | MC4R 1/4885MC3R 2/4885MC1R 5/4885 |
| US-20040138274-A1 | Cardiovascular disorders; hypotensive agents; endopeptidase inhibitor; sexual disorders | MME, ECE1, ECE2 | MC4R 3143/4885MC3R 2005/4885MC1R 3567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.